Literature DB >> 6106735

Pneumococcal vaccine and otitis media.

P H Mäkelä, M Sibakov, E Herva, J Henrichsen, J Luotonen, M Timonen, M Leinonen, M Koskela, J Pukander, S Pöntynen, P Grönroos, P Karma.   

Abstract

After an acute attack of otitis media 827 children aged 3 months to 6 years were assigned randomly to receive either 14-valent pneumococcal polysaccharide vaccine or a control vaccine (Haemophilus influenzae type b capsular polysaccharide). In children older than 6 months serum antibody responses to most of the vaccine polysaccharides were satisfactory. The response to type 6A was poor. Correspondingly, no clinical protection was seen below 6 months of age or against otitis media caused by group 6 pneumococci. Among the children more than 6 months old, the first 6 months after vaccination saw significantly (p < 0.001) fewer attacks caused by the pneumococal types represented in the vaccine (group 6 excepted) in those who received the pneumococcal vaccine than in those who received the control vaccine. Protection against type 19F was statistically significant (p < 0.01). The overall protective efficacy was 58%--somewhat better in children older than 2 years than in those younger. Previous attacks of otitis caused by pneumococci did not influence the protective efficacy of the vaccine.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6106735     DOI: 10.1016/s0140-6736(80)91989-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  23 in total

Review 1.  Conjugate vaccines.

Authors:  D Goldblatt
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

Review 2.  Mucosal immunology of vaccines against pathogenic nasopharyngeal bacteria.

Authors:  Q Zhang; A Finn
Journal:  J Clin Pathol       Date:  2004-10       Impact factor: 3.411

3.  Otitis media in children.

Authors:  A Ghaffar; W Feldman; J Dolovich
Journal:  Can Fam Physician       Date:  1981-09       Impact factor: 3.275

4.  Pneumonia in childhood: etiology and response to antimicrobial therapy.

Authors:  O Ruuskanen; H Nohynek; T Ziegler; R Capeding; H Rikalainen; P Huovinen; M Leinonen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-03       Impact factor: 3.267

Review 5.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

Review 6.  Newer vaccines--a review.

Authors:  A Kumar
Journal:  Indian J Pediatr       Date:  1983 Jul-Aug       Impact factor: 1.967

7.  Vaccination against pneumococcal disease.

Authors:  H P Lambert
Journal:  Arch Dis Child       Date:  1980-12       Impact factor: 3.791

Review 8.  What can children gain from pneumococcal conjugate vaccines?

Authors:  Heikki Peltola; Robert Booy; Heinz-Josef Schmitt
Journal:  Eur J Pediatr       Date:  2004-06-10       Impact factor: 3.183

9.  Plasma anti-pneumococcal antibody activity of the IgG class and subclasses in otitis prone children.

Authors:  A Freijd; L Hammarström; M A Persson; C I Smith
Journal:  Clin Exp Immunol       Date:  1984-05       Impact factor: 4.330

10.  Antibiotic-resistant pneumococci in hospitalized children.

Authors:  R M Robins-Browne; A B Kharsany; H J Koornhof
Journal:  J Hyg (Lond)       Date:  1984-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.